HC Wainwright & Co. Maintains Buy on Sensus Healthcare, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on Sensus Healthcare (NASDAQ:SRTS) and increased the price target from $8 to $10.
May 13, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The Buy rating by HC Wainwright & Co. with an increased price target from $8 to $10 suggests a positive outlook on Sensus Healthcare's stock.
The upgrade in the price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong conviction in the company's future performance and growth prospects. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100